News

Filter

Current filters:

IpsenPharmaceutical

1 to 9 of 105 results

Ipsen's Dysport gives positive results in adult and pediatric lower limb spasticity

Ipsen's Dysport gives positive results in adult and pediatric lower limb spasticity

26-01-2015

French drugmaker Ipsen has announced top line results from two double-blind Phase III trials of Dysport…

CNS DiseasesDysportFranceIpsenPharmaceuticalResearch

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Ipsen Phase III trial shows benefits of combining tamoxifen and triptorelin in breast cancer survival

Ipsen Phase III trial shows benefits of combining tamoxifen and triptorelin in breast cancer survival

12-12-2014

French drugmaker Ipsen has announced results of a trial evaluating the use of ovarian suppression as…

DecapeptylFranceIpsenOncologyPharmaceuticalResearchtamoxifentriptorelin pamoate

Ipsen’s Dysport accepted for review by US FDA

Ipsen’s Dysport accepted for review by US FDA

28-11-2014

French drugmaker Ipsen says that the US Food and Drug Administration has accepted for review its supplemental…

DysportIpsenNeurologicalPharmaceuticalRegulationUSA

Ipsen partners with academia to launch Archi-Pex research site

Ipsen partners with academia to launch Archi-Pex research site

21-11-2014

French drugmaker Ipsen and the French National Center for Scientific Research are to launch the Archi-Pex…

Cross-linked polyethyleneFranceIpsenPharmaceuticalProductionResearchSoftware

Otonomy and Ipsen in licensing agreement on gacyclidine for OTO-311 in tinnitus

Otonomy and Ipsen in licensing agreement on gacyclidine for OTO-311 in tinnitus

06-11-2014

Ear disease and disorder specialist Otonomy and French drugmaker Ipsen have entered into a licensing…

Auditory illusionsAuditory perceptiongacyclidineIpsenLicensingNeurologicalOtonomyPharmaceuticalTinnitus

Specialty care and Somatuline drive Ipsen's positive third quarter financials

Specialty care and Somatuline drive Ipsen's positive third quarter financials

29-10-2014

French drugmaker Ipsen has reported sales of 329 million euros ($419.1 million) for the third quarter…

DysportFinancialFranceIpsenPharmaceuticalSomatuline

1 to 9 of 105 results

COMPANY SPOTLIGHT

Menarini

Back to top